Literature DB >> 8995677

In vivo study of genetically simplified bovine leukemia virus derivatives that lack tax and rex.

K Boris-Lawrie1, V Altanerova, C Altaner, L Kucerova, H M Temin.   

Abstract

Genetically simplified derivatives of complex retroviruses that replicate in animal models are useful tools to study the role of the complex regulatory genes in virus infection and pathogenesis and were proposed as a novel approach toward the development of vaccines against complex retroviruses. Previously we developed genetically simple derivatives of bovine leukemia virus (BLV) that can replicate in tissue culture independently of the BLV regulatory proteins, Tax and Rex, and the RIII and GIV open reading frames (K. Boris-Lawrie and H. M. Temin, J. Virol. 69:1920-1924, 1995). These derivatives are encoded on novel, hybrid retrovirus genomes that contain transcriptional control sequences of a simple retrovirus and gag-pol or env genes of the complex BLV. The first-generation simple BLV derivatives replicate as complementary viruses (coviruses) by using separate gag-pol or env genomes, and therefore virus spread is limited to cells that are infected with both covirus genomes. Here we describe a second-generation simple BLV derivative that is encoded on a single hybrid genome. We show the virus to be replication competent by successive passage on D17 target cells and by analysis of viral RNA and proteins in the infected cells. Furthermore, we evaluate the immunogenicity and infectivity of the simple BLV derivatives in a BLV animal model. Small groups of rats were injected either with virus-producing cells or with proviral DNA. Western immunoblot analysis revealed that antibodies against the major viral antigenic determinants are induced in response to either method of introduction and that seroconversion is sustained in most of the rats for at least 6 months (the duration of the study). The magnitudes of the antiviral responses were similar in rats infected with the first-generation simple BLV coviruses, the second-generation replication-competent derivative, or wild-type BLV. Wild-type BLV typically infects peripheral blood mononuclear cells (PBMC), and the simple BLV derivatives were also found to infect PBMC as demonstrated by PCR amplification of proviral sequences and reverse transcriptase PCR amplification of viral RNA in treated rats. These results establish that simple BLV derivatives lacking tax and rex are infectious and immunogenic in rats. These viruses will be useful tools in comparative studies with BLV to evaluate the role of tax and rex in maintenance of virus load and in disease outcome.

Entities:  

Mesh:

Year:  1997        PMID: 8995677      PMCID: PMC191208     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  21 in total

1.  The defectiveness of Rous sarcoma virus.

Authors:  H HANAFUSA; T HANAFUSA; H RUBIN
Journal:  Proc Natl Acad Sci U S A       Date:  1963-04       Impact factor: 11.205

2.  Envelope glycoprotein gp51 of bovine leukemia virus is differently glycosylated in cells of various species and organ origin.

Authors:  C Altaner; M Merza; V Altanerova; B Morein
Journal:  Vet Immunol Immunopathol       Date:  1993-03       Impact factor: 2.046

3.  Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice.

Authors:  D Lew; S E Parker; T Latimer; A M Abai; A Kuwahara-Rundell; S G Doh; Z Y Yang; D Laface; S H Gromkowski; G J Nabel
Journal:  Hum Gene Ther       Date:  1995-05       Impact factor: 5.695

4.  New procedure for DNA transfection with polycation and dimethyl sulfoxide.

Authors:  S Kawai; M Nishizawa
Journal:  Mol Cell Biol       Date:  1984-06       Impact factor: 4.272

5.  The prevalence of proviral bovine leukemia virus in peripheral blood mononuclear cells at two subclinical stages of infection.

Authors:  M L Mirsky; C A Olmstead; Y Da; H A Lewin
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

6.  Evidence for the replication of bovine leukemia virus in the B lymphocytes.

Authors:  P S Paul; K A Pomeroy; D W Johnson; C C Muscoplat; B S Handwerger; F F Soper; D K Sorensen
Journal:  Am J Vet Res       Date:  1977-06       Impact factor: 1.156

7.  Transcription of bovine leukemia virus in peripheral blood cells obtained during early infection in vivo.

Authors:  K Radke; T J Sigala; D Grossman
Journal:  Microb Pathog       Date:  1992-05       Impact factor: 3.738

8.  Genetically simpler bovine leukemia virus derivatives can replicate independently of Tax and Rex.

Authors:  K Boris-Lawrie; H M Temin
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  A proposal for a new approach to a preventive vaccine against human immunodeficiency virus type 1.

Authors:  H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

10.  The bovine leukemia virus encapsidation signal is discontinuous and extends into the 5' end of the gag gene.

Authors:  L M Mansky; A E Krueger; H M Temin
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

View more
  14 in total

1.  Discordance between bovine leukemia virus tax immortalization in vitro and oncogenicity in vivo.

Authors:  J C Twizere; P Kerkhofs; A Burny; D Portetelle; R Kettmann; L Willems
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  gammadelta(+) T-Lp6phocyte cytotoxicity against envelope-expressing target cells is unique to the alymphocytic state of bovine leukemia virus infection in the natural host.

Authors:  P Lundberg; G A Splitter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  The 5' RNA terminus of spleen necrosis virus contains a novel posttranscriptional control element that facilitates human immunodeficiency virus Rev/RRE-independent Gag production.

Authors:  M Butsch; S Hull; Y Wang; T M Roberts; K Boris-Lawrie
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Bovine leukemia virus structural gene vectors are immunogenic and lack pathogenicity in a rabbit model.

Authors:  L Kucerova; V Altanerova; C Altaner; K Boris-Lawrie
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

5.  Long-term infection with retroviral structural gene vector provides protection against bovine leukemia virus disease in rabbits.

Authors:  Veronika Altanerova; Dana Holicova; Lucia Kucerova; Cestmir Altaner; Michael D Lairmore; Kathleen Boris-Lawrie
Journal:  Virology       Date:  2004-11-24       Impact factor: 3.616

6.  Construction and in vitro properties of a series of attenuated simian immunodeficiency viruses with all accessory genes deleted.

Authors:  Y Guan; J B Whitney; M Detorio; M A Wainberg
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

Review 7.  Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV.

Authors:  Sabrina M Rodríguez; Arnaud Florins; Nicolas Gillet; Alix de Brogniez; María Teresa Sánchez-Alcaraz; Mathieu Boxus; Fanny Boulanger; Gerónimo Gutiérrez; Karina Trono; Irene Alvarez; Lucas Vagnoni; Luc Willems
Journal:  Viruses       Date:  2011-07-19       Impact factor: 5.048

8.  Animal models on HTLV-1 and related viruses: what did we learn?

Authors:  Hiba El Hajj; Rihab Nasr; Youmna Kfoury; Zeina Dassouki; Roudaina Nasser; Ghada Kchour; Olivier Hermine; Hugues de Thé; Ali Bazarbachi
Journal:  Front Microbiol       Date:  2012-09-21       Impact factor: 5.640

9.  RNA helicase A interacts with divergent lymphotropic retroviruses and promotes translation of human T-cell leukemia virus type 1.

Authors:  Cheryl Bolinger; Alper Yilmaz; Tiffiney Roberts Hartman; Melinda Butsch Kovacic; Soledad Fernandez; Jianxin Ye; Mary Forget; Patrick L Green; Kathleen Boris-Lawrie
Journal:  Nucleic Acids Res       Date:  2007-04-10       Impact factor: 16.971

Review 10.  Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human.

Authors:  Nicolas Gillet; Arnaud Florins; Mathieu Boxus; Catherine Burteau; Annamaria Nigro; Fabian Vandermeers; Hervé Balon; Amel-Baya Bouzar; Julien Defoiche; Arsène Burny; Michal Reichert; Richard Kettmann; Luc Willems
Journal:  Retrovirology       Date:  2007-03-16       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.